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or Pharmacologic Stress Single-Photon Emission
omputed Tomography Myocardial Perfusion Imaging
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OBJECTIVES Regadenoson, a selective A2A adenosine receptor agonist, was evaluated for tolerability and
effectiveness as a pharmacological stress agent for detecting reversible myocardial hypoper-
fusion when combined with single-photon emission computed tomography (SPECT).
BACKGROUND Adenosine and dipyridamole are nonselective adenosine agonists currently used as pharma-
cologic stressors. Despite proven safety, these agents often cause undesirable side effects and
require a continuous infusion.
METHODS This Phase II, multicenter, open-label trial was conducted in 36 patients who had
demonstrated ischemia on a 6-min adenosine SPECT imaging study within the previous 2
to 46 days. Patients received regadenoson as a rapid intravenous bolus dose of 400 g (n 
18) or 500 g (n 18). The radiopharmaceutical was then delivered within one minute. The
SPECT images were acquired in a standard manner and uniformly processed at a central
laboratory. Regadenoson and adenosine studies were presented in random order and
interpreted blindly with a 17-segment model by three observers. Additionally, quantitative
analysis was performed with 4D-MSPECT software (University of Michigan, Ann Arbor,
Michigan).
RESULTS Overall agreement for the presence of reversible hypoperfusion was 86%. The 400-g dose
was better tolerated. Overall, regadenoson was well-tolerated; side effects (e.g., chest
discomfort, flushing, dyspnea) were generally mild in severity and self-limiting. High-grade
atrioventricular block and bronchospasm were not observed.
CONCLUSIONS Regadenoson is well-tolerated and seems as effective as adenosine for detecting and
quantifying the extent of hypoperfusion observed with SPECT perfusion imaging. Phase III
clinical trials are now underway, given the promise of regadenoson’s reduced side effects and
simplicity of bolus administration. (J Am Coll Cardiol 2005;46:2069–75) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.097American College of Cardiology Foundation
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ahe continued growth and expanding role of stress myo-
ardial perfusion imaging (MPI) mandates the development
f newer pharmacologic stressor agents that are simpler to
See page 2076
dminister, have an improved side effect profile, and offer
reater accessibility to patients who currently have contra-
ndications to other agents. Although exercise remains the
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ccepted May 18, 2005.referred modality of stress testing, many patients are
imited from completing a maximum stress test for a variety
f reasons. Presently, almost 50% of MPI performed in the
.S. is done with pharmacologic stress testing (1,2).
Pharmacologic single-photon emission computed tomog-
aphy (SPECT) MPI is most commonly performed with
asodilators to induce heterogeneous coronary blood flow
atterns in the setting of a hemodynamically significant
oronary artery stenosis (1–5). Adenosine and dipyridamole
ncrease coronary blood flow by coronary arteriolar vasodi-
atation, through stimulation of adenosine A2A receptors
6). Although these nonselective agonists have well-
stablished safety, the activation of adenosine A1, A2B, and
3 receptors can result in side effects, such as high-degree
trioventricular (AV) block and bronchospasm in suscepti-
le patients (7,8). Less serious side effects, such as flushing,
hortness of breath, and chest pain are bothersome in the
ajority of patients. In addition, the very short half-life of
denosine requires continuous infusion with a computerized
ump.
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Pharmacologic Stress Testing With Regadenoson December 6, 2005:2069–75The selective A2A agonist regadenoson (Fig. 1) has a
apid onset of action and, as a result of its low affinity, a
hort duration of effect (9,10). Upon rapid intravenous (IV)
olus administration, regadenoson increased coronary blood
ow velocity by more than 2.5-fold above baseline values for
t least two minutes (11), which is adequate for radionuclide
ptake. Owing to selective A2A adenosine receptor stimu-
ation and selective coronary vasodilatation, regadenoson is
nticipated to have a lower incidence of significant side
ffects and less effect on blood pressure than adenosine
9,11), and the bolus administration eliminates the need for
n infusion pump.
The current pilot study was performed to evaluate the
otential use of regadenoson as a new agent for pharmaco-
ogic stress in conjunction with SPECT MPI and to
etermine the optimal dose for use in Phase III trials.
ETHODS
tudy design. This Phase II, open-label, multicenter, non-
andomized pilot study was designed to evaluate the toler-
bility of regadenoson when administered by IV bolus for
se as a pharmacological stress agent in conjunction with
PECT MPI and to determine the comparability with
mages obtained with adenosine. Eligible patients had
ocumented reversible hypoperfusion on a clinically indi-
ated 6-min adenosine MPI study performed within 2 to 46
ays. No significant changes in clinical status or in medi-
ations were permitted during the interval between the
denosine scan and trial entry. Two non–weight-dependent
apid IV bolus doses were used: 400 g in the first 18
atients and 500 g in the second 18 patients.
ntry criteria. All imaging procedures were performed in
ccordance with guidelines established by the American
ociety of Nuclear Cardiology (12). Subjects were 18
ears of age and, if female, were not of child-bearing
otential. Institutional review board approval was obtained
t each institution, and all subjects provided written in-
ormed consent.
Subjects were excluded for any of the following reasons:
ercutaneous coronary intervention or coronary artery by-
ass graft surgery within one month or documented unsta-
le angina or acute myocardial infarction within three
onths of study entry, greater than first degree AV block,
eft bundle branch block or electronic ventricular pace-
Abbreviations and Acronyms
AV  atrioventricular
IV  intravenous
MPI  myocardial perfusion imaging
SBP  systolic blood pressure
SDS  summed difference score (SSS  SRS)
SPECT  single-photon emission computed tomography
SRS  summed rest score
SSS  summed stress scoreaker, decompensated heart failure, hemodynamic instabil-
2
2ty, left ventricular ejection fraction 35%, sick sinus
yndrome, cardiac transplantation, weight 250 lbs, con-
raindication to adenosine, currently receiving dipyridamole,
r had theophylline within 24 h of either scan. Subjects were
ot allowed methylxanthine-containing products (e.g., caf-
einated beverages) within 12 h of the study.
tress techniques. A 6-min adenosine protocol was per-
ormed with the radiopharmaceutical injection at three
inutes into the infusion. No adjunctive exercise was
erformed. Regadenoson was administered as a single pe-
ipheral IV bolus (10 s), followed by a 5-ml saline flush.
c-99m sestamibi or Tc-99m tetrofosmin (25 to 40 mCi)
as then administered IV over one to two seconds, 10 to
0 s after the 5-ml saline flush.
linical evaluation. Baseline assessment included a com-
lete medical history, physical examination, and laboratory
valuations including hematology, serum chemistry, and a
2-lead electrocardiogram (ECG). Blood pressure, heart
nd respiratory rates, and a 12-lead ECG were measured
gain before regadenoson administration and each minute
or 10 min and then at 15, 30, and 45 min after regadenoson
njection. The clinical assessment was repeated 24 to 72 min
ater. Tolerability was evaluated by collection of adverse
vents, laboratory profile, vital signs, and ECG measure-
ents during the study, with a telephone follow-up contact
4 to 18 days after study completion. Adverse events
eported by two or more subjects are included.
maging protocols. All commonly performed imaging
rotocols were permitted as long as the same radiopharma-
eutical and sequence were used for both studies. The dose
f the radiopharmaceutical and time to imaging between
tudies had to be within 10%. The SPECT acquisition was
o be performed within 90 min after drug administration.
amera and acquisition parameters were to be identical
etween studies. All gamma cameras were dual detector
ystems, with a 90° orientation.
PECT image analysis. Image data were transferred to
he nuclear cardiology core laboratory, which blinded each
tudy and performed uniform processing and display. Three
eaders evaluated the blinded images independently and,
hen, with a consensus (majority) interpretation. To reduce
otential bias, three normal studies and three studies with
xed defects were added to the study group images. The
igure 1. The molecular structure of regadenoson (CVT-3146; (1-{9-[(4S,
R, 3R, 5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2yl]-6aminopurin-
-yl}pyrazol-4-yl)-N-methylcarboxamide).
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December 6, 2005:2069–75 Pharmacologic Stress Testing With Regadenosonerfusion patterns were assessed with a 17-segment model
nd a semi-quantitative visual score on a five-point scale
rom zero (normal) to four (no activity) (13). Summed
cores for stress (SSS) and rest (SRS) were determined, and
ummed scores for differences (SDS  SSS  SRS) were
alculated to represent the extent and severity of reversible
erfusion defects. Additionally, a blinded, direct, same-
creen comparison of the adenosine and regadenoson stress
mages was performed to determine relative differences in
he extent and severity of ischemic defects using five regions
apical, anterior, inferior, lateral, and septal), with a single
esting study (from the adenosine examination). Quantita-
ive analysis was also done with 4D-MSPECT (University
f Michigan, Ann Arbor, Michigan).
tatistical analysis. The current trial was designed as a
ilot study; 18 subjects per dose group were considered
dequate to provide an initial assessment of safety and
olerability. All analyses were performed with SAS Release
.1 for Windows (SAS Institute, Cary, North Carolina)
14). Regadenoson/adenosine image agreements were de-
ermined; square tables that cross-classified patients by their
denosine and regadenoson image assessments were pre-
ared, and the assessment pairs falling in the diagonal cells
f the table were considered to be in agreement. Agreement
ates were tabulated by regadenoson dose group, and 90%
lopper-Pearson confidence intervals for agreement rates
ere computed (15).
ESULTS
etween August 2002 and January 2003, 36 subjects were
nrolled from four study sites and received one of two
ifferent doses of regadenoson, 400 g (n  18) or 500 g
n  18). Baseline demographics and medical history are
ummarized in Table 1. Protocols used were single day
tress/rest Tc-99m sestamibi (n  16), single day rest/stress
able 1. Demographics and Baseline Medical History
Characteristic
All
Patients
(n  36)
400 g
Regadenoson
(n  18)
500 g
Regadenoson
(n  18)
ge, yrs, mean (SD) 67.3 (9.5) 66.0 (10.5) 68.5 (8.6)
ale 27 (75) 13 (72) 14 (78)
ace
Caucasian 25 (69) 10 (56) 15 (83)
African American 5 (14) 4 (22) 1 (6)
Hispanic 5 (14) 3 (17) 2 (11)
Asian 1 (3) 1 (6) 0 (0)
eight, kg, mean (SD) 90.2 (19.5) 89.3 (22.2) 91.1 (17.0)
MI, kg/m2, mean (SD) 30.3 (5.9) 30.1 (5.8) 30.6 (6.2)
re-existing condition
or procedure
CAD 35 (97) 18 (100) 17 (94)
Hypertension 34 (94) 17 (94) 17 (94)
Angina 28 (78) 13 (72) 15 (83)
PCI 22 (61) 10 (56) 12 (67)
CABG 19 (53) 10 (56) 9 (50)
alues are n (%) unless otherwise indicated.m
BMI body mass index; CABG coronary artery bypass graft; CAD coronary
rtery disease; PCI  percutaneous coronary intervention.c-99m sestamibi (n  7), rest thallium/stress Tc-99m
estamibi (n  12), and rest thallium/stress Tc-99m tetro-
osmin (n  1). One patient (500-g group) was excluded
rom image analysis, because adenosine images were inad-
ertently erased and were unavailable for comparison. Time
etween radiopharmaceutical injection and image acquisi-
ion was 45 to 147 min.
emodynamic effects of regadenoson. Table 2 summa-
izes the hemodynamic changes that occurred with regade-
oson administration. Heart rate increased for both dose
roups; a greater, but not statistically different effect was
bserved in the 500-g group. A heart rate100 beats/min
as noted in seven subjects (19%), with a maximum
bserved heart rate of 115 beats/min. The mean maximum
hange from baseline was 21 and 24 beats/min for the
00-g and 500-g groups, respectively. The maximum
hange occurred within approximately two minutes after
egadenoson administration (Fig. 2A). Two-thirds of the
atients returned to near-baseline (within 10 beats/min)
eart rate within 15 min after regadenoson administration.
The mean systolic blood pressure (SBP) and diastolic
lood pressure decreased in both dose groups, with 500-g
ubjects showing a trend (p  0.091) for a greater and more
ustained mean decrease in SBP (Table 2; Fig. 2B). De-
reases in SBP 25 mm Hg were observed in six patients:
ne patient in the 400-g group and five patients in the
00-g group. Hypotension (SBP 90 mm Hg) was noted
n one subject (500-g dose). For SBP, the greatest mean
ecrease from baseline occurred at three minutes after dose
n the 400-g group and at four minutes after dose in the
00-g group.
PECT imaging. The blinded consensus interpretation of
he adenosine SPECT images confirmed the presence of
yocardial ischemia in all 35 subjects, as compared with
9% (16 of 18) and 82% (14 of 17) of the scans obtained
ith 400 or 500 g regadenoson, respectively. Agreement
or the presence of reversible hypoperfusion was calculated
n the basis of the majority of the three independent ratings,
hich demonstrated 89% agreement with the 400-g dose
nd 76% for the 500-g group. An example of the images
btained with adenosine and regadenoson is shown in
igure 3.
When the two regadenoson doses are combined, agree-
able 2. Mean Maximum Hemodynamic Changes With
egadenoson
Variable
Combined
(n  36)
400 g
Regadenoson
(n  18)
500 g
Regadenoson
(n  18)
eart rate, beats/min* 24 (11) 21 (10) 26 (12)
ystolic blood
pressure, mm Hg†
14 (10) 11 (8) 17 (12)
iastolic blood
pressure, mm Hg
10 (7) 11 (6) 9 (8)
alues are means (SD). *Maximum heart rate observed at 1 min. †Maximum decrease
n systolic blood pressure at 4 min.ent rates between adenosine- and regadenoson-induced
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Pharmacologic Stress Testing With Regadenoson December 6, 2005:2069–75erfusion defects by coronary artery vascular territory are as
ollows: 86% for the right coronary artery, 80% for the left
nterior descending coronary artery, and 77% for the left
ircumflex coronary artery.
The severity of the defect, as determined by the SSS, was
ssessed both visually, on the basis of the average of the
ndependent reviews, and quantitatively, by 4D-MSPECT
Table 3). By both methods, the summed scores were
rouped as follows: 0 to 3, 4 to 7, 8 to 11, and 12. For the
isual SSS assessment, the overall regadenoson/adenosine
greement was 57%. The computerized software assessment
howed an overall regadenoson/adenosine agreement of
9%. No significant difference was present in the visual or
uantitative summed scores between adenosine and regade-
igure 2. Change in heart rate in beats/min (A) and in systolic blood pres
eans with standard errors. Open squares  400 g; solid squares  5oson (Table 3). rIn the same-screen comparison of the 175 regions (5
egions per patient, n  35) on the regadenoson and
denosine stress images, the extent of the ischemic region
as less in 9 regions and greater in 15 regions, yielding an
verall rate of agreement of 86%.
afety and tolerability. Reported side effects are summa-
ized in Table 4. Most side effects were considered mild and
ransient, resolving spontaneously within 10 min. Of the 26
ubjects experiencing any symptoms, 77% categorized their
ymptoms as mild, with 88% of all reported adverse events
eing mild (83 of 94). A higher proportion of patients
eceiving the 500-g dose group reported flushing, dyspnea,
nd dizziness compared with the 400-g group, although
hese differences were not statistically significant. Two subjects
n mm Hg (B) from baseline after regadenoson administration; values are
.sure ieceiving regadenoson (400 g), experienced severe adverse
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December 6, 2005:2069–75 Pharmacologic Stress Testing With Regadenosonffects, which were not reported as occurring with adenosine.
ne subject reported a worsening of migraine headache,
equiring a hospital stay. A second subject had chest pain and
eadache, which quickly subsided after treatment with 100 mg
f IV aminophylline. The clinical laboratory profile (hematol-
gy, serum chemistry, and urinalysis) for all patients was either
ormal during the study or reflected changes in laboratory
alues that were not clinically significant.
lectrocardiographic findings. Six patients had episodes
f transient ST-segment depression (range of 0.5 to 3 mm),
igure 3. Direct comparison of adenosine and regadenoson images using
mages reveal a large, mild, reversible perfusion defect in the anterior, apical,
tress images. Upper panel is the regadenoson study.
Table 3. Imaging Visual and Quantitative Sum
Visual†
Summed Score* Regadenoson
Rest (SRS) 5.0 (4.8)
Stress (SSS) 13.2 (7.7)
Difference (SDS) 8.2 (5.9)
Values are means (SD); all pair-wise comparisons are not stat
were measured; summed scores for differences (SDS) were cal
a semiquantitative visual score on a five-point scale from zero (norma
by 4D-MSPECT.ccurring within one minute after dose and resolving by 30
in. No second- or third-degree AV block occurred with
egadenoson; one patient (in the 400-g group) developed
rst-degree AV block. No clinically significant or sustained
ctopy was noted after regadenoson.
ISCUSSION
his is this first study examining the clinical utility of
egadenoson, a selective adenosine A2A agonist, in conjunc-
-isotope protocol (rest: thallium-201, stress: Tc-99m tetrofosmin). These
ateral walls. Similar findings were noted on the adenosine and regadenoson
Scores by Pharmacologic Stress Agent
Quantitative‡
osine Regadenoson Adenosine
(5.2) 6.2 (6.8) 6.4 (6.8)
(8.8) 13.6 (9.5) 13.7 (9.0)
(6.4) 8.0 (5.6) 7.9 (5.3)
y significant. *Summed scores for stress (SSS) and rest (SRS)
(SSSSRS). †Visual analysis used a 17-segment model anda dualmed
Aden
4.8
13.9
9.1
isticall
culatedl) to four (no activity). ‡Quantitative analysis was performed
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Pharmacologic Stress Testing With Regadenoson December 6, 2005:2069–75ion with SPECT MPI. These results demonstrate that
egadenoson is well-tolerated and yields images comparable
o those obtained with adenosine. Agreement between
egadenoson and adenosine for detecting ischemia was good
nd not dose-dependent. Regional agreement for detection
f stress perfusion defects in all three major vascular
erritories was also good (76% to 89%) and comparable to
hat reported for adenosine and exercise stress in a large
ivotal trial (5).
The hemodynamic effects and their temporal changes
ith regadenoson are consistent with earlier animal exper-
ments (9,11) and indicate a rapid physiological response
16). The magnitude of blood pressure decrease with rega-
enoson was less than that commonly observed for adeno-
ine or other vasodilators (1,2,7,17), presumably owing to its
referential effects on the coronary vasculature. A SBP of
100 mm Hg was observed in three 500-g dose subjects.
he increase in heart rate with regadenoson of 20 to 24
eats/min is similar to that reported for both adenosine and
ipyridamole (1,2,7) as well as with binodenoson (17). The
ncrease of heart rate is greater than can be accounted for by
he blood pressure decrease with regadenoson. The physi-
logical basis for the increase in heart rate is likely to be
irect neurohumoral activation through stimulation of post-
anglionic norepinephrine release (18).
Adverse events associated with regadenoson administra-
ion were generally mild in severity and short in duration.
otably, the absence of AV block and bronchospasm
uggest that regadenoson might serve as an alternative
tressor to adenosine in at-risk patients. The higher dose of
egadenoson used in this study was associated with a greater
ncidence of adverse effects, although these differences were
ot statistically significant. Overall, side effects noted with
egadenoson were less frequent than previously reported
ith adenosine (7) and similar to those recently reported
ith binodenoson (17), although no direct comparison
etween these compounds and regadenoson has been per-
ormed.
The agreement between adenosine and regadenoson was
lightly lower in this trial than noted in a recently published
able 4. Adverse Events Associated With Regadenoson
dministration
Both
Doses
(n  36)
400 g
Regadenoson
(n  18)
500 g
Regadenoson
(n  18)
hest pain 12 (33) 6 (33) 6 (33)
eadache 9 (25) 4 (22) 5 (28)
bdominal pain 4 (11) 3 (17) 1 (6)
lushing 11 (31) 3 (17) 8 (44)
alpitation 2 (6) 2 (11) 0 (0)
yspnea 11 (31) 3 (17) 8 (44)
izziness 7 (19) 2 (11) 5 (28)
ypesthesia 3 (8) 2 (11) 1 (6)
otals 26 (72) 11 (61) 15 (83)
alues are n (%).tudy comparing adenosine with binodenoson (17). In thattudy, the agreement for comparing the extent and severity
f ischemia was between 79% and 85%; however, this latter
tudy simultaneously compared the stress/rest adenosine
nd binodenoson images from a single screen display rather
han performing independent image interpretation, which
ikely improved the agreement. Furthermore, the binode-
oson protocol did not restrict subjects to those who have
schemia; examining subjects with an SDS 2 in that study
rovided an agreement rate of 56% to 73%, comparable to
hat noted in the current regadenoson trial (17).
Finally, the higher dose of regadenoson used in this study
as associated with a greater incidence of adverse effects,
lthough these differences were not statistically significant.
ecause the concordance with adenosine was similar for
oth doses (400 and 500 g), the 400-g dose was selected
or phase III clinical trials.
The current study was a pilot, dose-ranging trial and was
ot powered to demonstrate efficacy. Another potential
imitation of the study is that the subjects were not ran-
omly assigned to dose groups and, therefore, bias might be
resent. Other limitations include the use of multiple
maging protocols and a lack of gender and racial diversity.
onclusions. Regadenoson, a selective A2A receptor ago-
ist, is a well-tolerated, pharmacologic stress agent for
PECT MPI and seems to produce similar regions of
ypoperfusion as noted with adenosine. Regadenoson in-
reases heart rate in a similar magnitude to that reported for
denosine, but with less impact on SBP. Side effects are
enerally mild in severity and short in duration, with no
ssociated high-degree AV block or bronchospasm. The
00-g dose of regadenoson seems to be better tolerated
han the 500-g dose. Because the agreement with adenosine
as similar for both doses studied, our findings support
dditional clinical investigation with the 400-g dose of this
ovel pharmacologic stress agent.
eprint requests and correspondence: Dr. Robert C. Hendel,
12 Northwest Highway, Suite 7, Fox River Grove, Illinois.
-mail: rhendel@midwestheart.org.
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